Aligos Therapeutics, Inc. (ALGS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
One Corporate Drive
South San Francisco, CA 94080
United States of America (the)
Phone
800 466 6059
Website
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
October 16, 2020
| Name | Title | Pay | Year Born |
| Lawrence Blatt | Chief Executive Officer, President & Chairman of the Board | 1.04M | 1962 |
| Julian A. Symons DPHIL | Executive Vice President & Chief Scientific Officer | 693,977 | 1962 |
| Lesley Ann Calhoun | Executive Vice President, Chief Financial Officer & Chief Operating Officer | 704,760 | 1966 |
| David Smith | Executive Vice President & Head of Chemical Operations | 0 | N/A |
| Kieron Wesson | Vice President & Head of Chemistry Manufacturing Controls | 0 | N/A |
| Tse-I Lin | Senior Vice President of Early Compound Development & Belgian Site Head | 0 | N/A |
| Nikhil Aneja | Principal Accounting Officer | 0 | 1977 |
| Kristina Engeseth | Senior Vice President and Head of People & Culture | 0 | N/A |
| Ramon Polo | Senior VP & Head of Global Regulatory Affairs | 0 | N/A |
| Sushmita Chanda DABT | Executive Vice President & Chief Development Officer | 0 | 1967 |
| James Hassard | Executive VP & Chief Commercial Officer | 0 | 1967 |
| Laura Kavanaugh | Vice President & Head of Legal | 0 | N/A |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.